• Is video-assisted thoracoscopic lobectomy associated with higher overall costs compared with open surgery? A review of the literature until May 2020 was performed, and 20 studies provided the most applicable evidence to evaluate this issue.
• Thoracoscopic lobectomy was associated with higher operative costs than open lobectomy, but lower indirect costs. It translated into lower overall costs for thoracoscopic than for open lobectomy in 10 studies, similar in seven, and higher in three studies.
• The worry that thoracoscopic lobectomy might be associated with increased total cost is thus not warranted, and should not be used as an excuse against the use of thoracoscopy in surgery for early stage lung cancers.

This is the first report of the prevalence of driver mutations in Brazilian NSCLC patients using comprehensive genomic profiling.

Two types of mutations in the promoter region of Polb gene, -168C>A and -188_-187insCGCCC, are associated with thymic hyperplasia and may become the new risk factors for this disease.

Anlotinib had an inhibitory effect on lung cancer H520 cell proliferation. Anlotinib combined with radiotherapy was able to synergistically inhibit tumor cell growth.

The baseline C-reactive protein:albumin ratio was significantly associated with overall survival in non-small cell lung cancer patients treated with nivolumab monotherapy. The time-series change of this marker may be useful in predicting the treatment efficacy with nivolumab.

Swimmers plot of atezolizumab according to the efficacy of prior anti-PD-1 treatment. Seven patients (18.4%, 7/38) continued atezolizumab over four months as an ICI retreatment.

NY-ESO-1 or LAG-3 expression in patients with high PD-L1 expression was significantly associated with a favorable OS and PFS for immunotherapy in NSCLC. Moreover, LAG-3 and NY-ESO-1 co-expression was considered as a predictable marker for survival outcome and LAG-3 showed a good negative predictive value.

Third-generation EGFR-TKIs overcome EGFR T790M-meditated resistance. However, amplified EGFR confers resistance to third-generation EGFR-TKIs. Inhibiting HSP90, a chaperon for EGFR, suppresses the proliferation of EGFR-amplified cells by degrading EGFR in vitro, providing a preclinical rationale for the use of HSP90 inhibitors to overcome the EGFR amplification-meditated resistance.

We evaluated the efficacy and safety of crizotinib in patients with ALK-positive non-small cell lung cancer refractory to alectinib. We included nine patients and stipulated an overall response rate (ORR) of 50% and a lower limit of interest of 15%. The ORR was 33.3%, failing to meet the criteria. However, the treatment showed efficacy alongside tolerable adverse effects.

This study investigated the expression level of HN1L in AEG and adjacent nontumor tissues and further explored the correlation between HN1L expression and clinical parameters, confirming the regulatory effect of HN1L on the malignant proliferation of AEG. We found that knockdown of HN1L could effectively inhibit tumor growth, invasion, and metastasis, which indicates that HN1L may be a potential therapeutic target for AEG patients.

Our findings reveal cancer-specific changes of SNORD55 in platelets of NSCLC, which paving the way for the exploitation of sensitive and specific NSCLC diagnostic biomarker either alone or in combination, providing certain basis for clinical projects of TEP SNORD55 in early screening of NSCLC.

We assessed GPS and AE-ILD/prognosis in patients with NSCLC and ILD.

DWIBS has benefits of diagnostic accuracy and is less expensive in medical costs for the detection of a relapse. DWIBS could potentially replace PET-CT after lung cancer resection.

PTA shows stable hemodynamics, but the risk of rupture is extremely high and frequently fatal. To assist in the differential diagnoses, clinicians need to be familiar with imaging findings of PTA.

We analyzed the origin and evolution of lung adenocarcinoma based on the WES results of MPLC in one individual. Analysis of the WES results reflects a progressive genomic evolution at the single nucleotide level, which we believe supports the lung adenocarcinoma model from AAH to MIA and ADC. Meanwhile, we explored possible potential driver genes and therapeutic targets.

Our case illustrates the complexity of ICI-associated immune modulation in tuberculosis. Since new lesions in lung cancer patients are commonly associated with tumor progression, infections with mycobacterial tuberculosis may be underdiagnosed in lung cancer.

This is a report of a 36-year-old female with a ground-glass nodule in the left lingual segment determined on computed tomography (CT) who successfully underwent 1 cm incision uniportal thoracoscopic lingulectomy. This procedure is technically safe and feasible in selected patients and produces better cosmetic results than traditional thoracoscopic surgery.

This is a rare case report of tegafur-uracil-induced pericardial effusion that mimics a malignant pericardial effusion in a patient with primary lung cancer. In cases of pericardial effusion without symptoms and no suspicious metastatic lesions in other organs, we should be concerned about tegafur-uracil-induced pericardial effusion, and short-term follow-up after discontinuation of tegafur-uracil should be recommended.

This is the first case of synchronous triple primary lung cancer with different histological subtypes in the same lobe of the lung.

Little has been reported on acquired resistance mechanisms to lorlatinib. Here, we report a case of a patient with ALK-positive lung adenocarcinoma that acquired resistance to lorlatinib during treatment for brain metastasis and showed histological transformation to squamous cell carcinoma with MET amplification. We also review the previous literature on the resistance mechanism to ALK inhibitors.

This report describes a 78-year-old man with renal cell carcinoma treated with nivolumab and ipilimumab immunotherapy and is the first reported case of eosinophilic pneumonia caused by treatment with combined immune checkpoint inhibitors (ICIs).

We constructed an umbrella-type lung cancer patient registry (CS-Lung-003) integrating multiple related prospective observational studies (linked studies) that reflect clinical questions about lung cancer treatment. Under this single registry, researchers collaborate on patient registration and data provision for their own and other studies.